QLT/Novartis Visudyne Occult Data Expected 2004; Medicare Coverage Denied
This article was originally published in The Gray Sheet
Executive Summary
QLT expects to have data on Visudyne in age-related macular degeneration patients with occult lesions from an ongoing Canadian and European trial by 2004
You may also be interested in...
Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members
Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
Coverage of ocular photodynamic therapy with QLT/Novartis' Visudyne (verteporfin) in patients who have age-related macular degeneration and occult lesions with no classic choroidal neovascularization (CNV) should be restricted to those with small lesions, according to several MCAC panel members
Medicare Appeals Rule Expedited By Visudyne Settlement; MCAC To Convene
CMS' Medicare Coverage Advisory Committee will review initial data from QLT, Inc.'s Phase III trial investigating Visudyne (verteporfin) ocular photodynamic therapy in age-related macular degeneration patients with occult lesions